Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV

Guan‐Jhou Chen(National Taiwan University Hospital), Li-Shin Su(National Taiwan University Hospital), Kuan‐Yin Lin(National Taiwan University), Sui‐Yuan Chang(National Taiwan University of Science and Technology), Yu‐Shan Huang(Capital Medical University), Shih‐Ping Lin, Min-Han Hsieh(Kaohsiung Medical University), Chungeng Liu(Union Hospital), Shu‐Hsing Cheng(Ministry of Health and Welfare), Chien‐Yu Cheng(Tao Yuan General Hospital), Tung-Che Hung, Chi-Ying Lin, Huei-Chun Ku, Hsin‐Yun Sun(National Taiwan University Hospital), Yu‐Chung Chuang(National Taiwan University Hospital), Chien‐Ching Hung(National Taiwan University), Hsiu‐Wen Wang(Oak Ridge National Laboratory), Yuan‐Ti Lee(Chung Shan Medical University Hospital), Ning‐Chi Wang(Tri-Service General Hospital), Pei‐Ying Wu(Shanghai Jiao Tong University), Chia-Yin Hsieh(National Taiwan University Hospital), Sung‐Hsi Huang(National Taiwan University), Yi‐Chieh Lee(Luodong Poh-Ai Hospital), Yi‐Ching Su(National Taiwan University Hospital), Yi‐Chia Huang(National Taiwan University Hospital), Te‐Yu Lin, Hung-Jen Tang(Chi Mei Medical Center), Wen‐Chun Liu(National Taiwan University Hospital), Mao‐Wang Ho
Journal of Antimicrobial Chemotherapy
June 15, 2020
Cited by 8


Related Papers